# OnCo record mondego-bio (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/mondego-bio/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "mondego-bio" ;
  schema:name "Mondego Bio"@en ;
  schema:alternateName "Mondego"@en ;
  schema:description "Mondego Bio, in Portugal, is developing a tablet-type drug that blocks PTPN2, a protein that dampens the immune system's response to cancer, with the aim of making immunotherapy work better. It planned its first human study for 2026."@en ;
  schema:url <https://onco.cc/companies/mondego-bio/>, <https://www.mondegobio.com/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.mondegobio.com/>, <https://www.mondegobio.com/2025/09/18/biovance-capital-leads-series-a-financing-in-mondego-bio-together-with-orbimed-and-torrey-pines/>, <https://www.mondegobio.com/2025/12/22/mondego-bio-announces-selection-of-a-ptpn2-inhibitor-clinical-candidate-and-targets-first-in-human-trials-in-h1-2026/>, <https://www.orbimed.com/portfolio/> ;
  schema:addressCountry "PT" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/ai-drug-design/> .